Overview

A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to measure the efficacy of ABT-SLV187 in subjects with advanced Parkinson's disease.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie
Treatments:
Antiparkinson Agents
Carbidopa
Carbidopa, levodopa drug combination
Levodopa